This patient did not require blood component transfusions, G-CSF, or rhTPO during trilaciclib-protected cycles, except for rhTPO administration for Grade II thrombocytopenia occurring only in cycles 2 and 5. The gene discussed is CSF3; the disease is Thrombocytopenia.